We showed that multiple DDR pathways are essential for the response to platinum drugs, that targeting the NER pathway potentiates the effects of platinum drugs regardless of the DLBCL subtype, and that BTK can be targeted to sensitize DLBCL cells to cisplatin and carboplatin. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.